Takeaways: Exdensur positions GSK as the first biologic in Canada with twice-yearly dosing for severe eosinophilic asthma, a major convenience advantage over existing IL‑4/5...
Takeaways: Health Canada’s decision makes Nucala the first biologic add‑on for eosinophilic COPD in Canada, opening a new high-value segment on top of triple inhaled therapy for patients with fr...
Takeaways: UM171 was discovered at Université de Montréal, so this deal keeps a Canadian‑origin innovation tied to a Canadian commercial partner, aligning with domestic priorities around life‑sc...
